Comparative Pharmacology
Head-to-head clinical analysis: MICRAININ versus TREZIX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MICRAININ versus TREZIX.
MICRAININ vs TREZIX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MICRAININ is a combination of acetaminophen (paracetamol) and butalbital. Acetaminophen inhibits cyclooxygenase (COX) enzymes in the central nervous system, reducing prostaglandin synthesis and modulating pain perception via activation of descending serotonergic pathways. Butalbital is a barbiturate that enhances GABA-A receptor activity, increasing chloride ion conductance and causing central nervous system depression.
Capsaicin is a TRPV1 receptor agonist that initially causes pain and neuropeptide release, followed by desensitization and depletion of substance P from sensory nerve terminals, reducing pain transmission. Hydrocodone is a mu-opioid receptor agonist, modulating pain perception. Acetaminophen inhibits cyclooxygenase (COX) enzymes, primarily in the central nervous system, reducing prostaglandin synthesis and pain signaling.
2 tablets orally at onset of migraine, then 1 tablet every 1-2 hours as needed, up to 4 tablets per attack, not to exceed 6 tablets per day. Each tablet contains isometheptene mucate 65 mg, dichloralphenazone 100 mg, and acetaminophen 325 mg.
TREZIX (acetaminophen 320 mg, dichloralphenazone 100 mg, isometheptene mucate 65 mg) capsules: 2 capsules orally at onset of headache, then 1 capsule every hour until relief (maximum 5 capsules in 12 hours, 10 capsules in 24 hours). For migraine: 2 capsules orally at onset, then 1 capsule every hour as needed (maximum 5 capsules per attack).
None Documented
None Documented
Terminal elimination half-life 8-12 hours; in elderly or severe renal impairment, may extend to 24 hours
Terminal elimination half-life is approximately 2.5-3.5 hours for the parent compound; clinically, this necessitates dosing every 4-6 hours for sustained effect during wakefulness, but accumulation is minimal with normal hepatic and renal function.
Primarily renal (70% unchanged, 20% as sulfate conjugate); biliary/fecal <10%
Renal excretion of metabolites (primarily as glucuronide conjugates and unchanged drug) accounts for approximately 55-65% of the dose; biliary/fecal elimination accounts for approximately 25-35%.
Category C
Category C
Barbiturate Combination Analgesic
Barbiturate Combination Analgesic